within range
Long-term success typically involves continued treatment, transition to a maintenance dose, or a structured lifestyle plan discussed with your doctor toward the end of your active titration
For instance, patients with a history of pancreatitis should exercise caution, and those with personal or family histories of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should avoid GLP-1 receptor agonists, as rodent studies have indicated a potential risk of thyroid tumors
Q&A 111: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) Should I start tirzepatide or semaglutide to treat my MS
If your retatrutide seems less effective than it was, if appetite suppression has weakened, or if results have stalled despite consistent dosing, potency loss from improper storage should be one of the first things you investigate
A 2023 pharmacokinetic study published in Diabetes, Obesity and Metabolism confirmed that semaglutide delays gastric half-emptying time by approximately 33% at steady state [1]